AI Stocks Under 10 Dollars
Discover investment opportunities in AI Stocks Under 10 Dollars using our Smart AI Filter.
AI is processing your request...
AI is analyzing your request
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Stocks Under 10 Dollars using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Stocks Under 10 Dollars using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Stocks Under 10 Dollars using our Smart AI Filter.
9 stocks found for "AI Stocks Under 10 Dollars"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
---|---|---|---|---|---|---|
0.48 | ±92.0% | -0.2 | 0.00% | |||
1.03 | ±69.8% | -35.5 | 0.00% | |||
0.68 | ±100.0% | -38.7 | 0.00% | |||
0.57 | ±78.0% | — | 0.00% | |||
0.52 | ±100.0% | 12.6 | 18.35% | |||
1.55 | ±100.0% | -7.7 | 0.00% | |||
0.97 | ±100.0% | -55.4 | 0.00% | |||
0.78 | ±72.7% | 6.4 | 0.00% | |||
1.19 | ±68.3% | -57.3 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How do the technical indicators for the AI stock BBAI under $10 appear?
A: The AI stock BBAI often trades below its 50-day and 200-day moving averages, indicating potential short-term and medium-term bearish sentiment. Investors may consider further examining trading volume and RSI for insight into momentum.
Q: Is the AI company LTRX known for dividend payments?
A: LTRX, an AI-centric firm, does not typically distribute dividends, as it primarily reinvests profits into growth and technological development, characteristic of smaller tech-focused companies.
Q: What are some risks associated with investing in the under-$10 AI stock REKR?
A: REKR, a sub-$10 AI stock, faces risks including limited liquidity, high volatility, and challenges in scaling operations. These factors can affect its share price stability and long-term performance.
Q: How might economic downturns impact NOTE, a stock under $10?
A: NOTE could face challenges during economic downturns, as budget constraints may lead to reduced spending on AI innovations and limit the company's growth prospects in tougher markets.
Q: What opportunities does DUOT present in the AI sector?
A: DUOT offers potential opportunities within AI by innovating in intelligent analytics for railways and transportation. Its niche focus may position it advantageously to benefit from modernization trends in transport infrastructure.
Q: Could POAI's focus on personalized oncology create a differentiated appeal?
A: POAI's dedication to personalized cancer treatment through AI may attract investors interested in the healthcare-tech convergence, potentially offering a unique competitive advantage in the precision medicine field.
BigBear.ai (NYSE: BBAI), an AI solutions provider focused on national security, has dropped nearly 30% over the past month to $5. Despite this pullback, the stock still trades at a stretched nine times trailing revenue—well above its historical average of three times.
Read moreBiotechnology firms are increasingly turning to innovative combination therapies to tackle hard-to-treat cancers, with promising results sparking investor interest. AIM ImmunoTech Inc. AIM is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.
Read more